Disclosure of elevated amyloid status is not associated with long‐term suicidality in a preclinical AD trial

• Published in: Alzheimer's & dementia Vol. 21; no. 2; pp. e14623 - n/a
• Main Authors: Grill, Joshua D., Raman, Rema, Flournoy, Charlene, Ernstrom, Karin, Pierce, Aimee, Smith, Amanda, Rosenberg, Paul, Burns, Jeffrey, Karlawish, Jason, Aisen, Paul, Holdridge, Karen Chilcott, Mancini, Michele, Sperling, Reisa, Sultzer, David
• Format: Journal Article
• Language: English
• Published: United States John Wiley and Sons Inc 01.02.2025
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - metabolism; Alzheimer Disease - psychology; Amyloid - metabolism; Amyloid beta-Peptides - metabolism; biomarker; Biomarkers - metabolism; Brain - diagnostic imaging; Brain - metabolism; Cohort Studies; Disclosure; Female; Humans; Male; Middle Aged; Positron-Emission Tomography; preclinical; Short Report; Suicidal Ideation; suicide; Suicide - psychology; disclosure; biomarker; preclinical; suicide

INTRODUCTION The long‐term implications of disclosing Alzheimer's disease (AD) biomarker information to cognitively unimpaired individuals are unknown. METHODS We compared participants who disclosed their elevated amyloid imaging result in a preclinical AD trial to those who disclosed a not ele...